Anti-Müllerian hormone plasma levels in spontaneous menstrual cycle and during treatment with FSH to induce ovulation.
about
A validated model of serum anti-müllerian hormone from conception to menopauseRole of Anti-Müllerian Hormone in pathophysiology, diagnosis and treatment of Polycystic Ovary Syndrome: a reviewDisordered follicle developmentThe ageing ovary and uterus: new biological insightsBiologic markers of ovarian reserve and reproductive aging: application in a cohort study of HIV infection in womenFSH and its second messenger cAMP stimulate the transcription of human anti-Müllerian hormone in cultured granulosa cells.Biological variability in serum anti-Müllerian hormone throughout the menstrual cycle in ovulatory and sporadic anovulatory cycles in eumenorrheic women.Anti-Müllerian hormone and inhibin B variability during normal menstrual cycles.Clinical pregnancy in a woman with idiopathic hypogonadotropic hypogonadism and low AMH: utility of ovarian reserve markers in IHHAnti-Müllerian hormone serum values and ovarian reserve: can it predict a decrease in fertility after ovarian stimulation by ART cycles?Anti-Müllerian hormone and progesterone levels produced by granulosa cells are higher when derived from natural cycle IVF than from conventional gonadotropin-stimulated IVF.Variations in serum müllerian inhibiting substance between white, black, and Hispanic women.Role of baseline antral follicle count and anti-Mullerian hormone in prediction of cumulative live birth in the first in vitro fertilisation cycle: a retrospective cohort analysis.Reclaiming fertility awareness methods to inform timed intercourse for HIV serodiscordant couples attempting to conceiveWhat number of oocytes is appropriate for defining poor ovarian response?Biomarker prediction of chemotherapy-related amenorrhea in premenopausal women with breast cancer participating in E5103.Anti-mullerian hormone as a predictive marker for the selection of women for oocyte in vitro maturation treatmentSerum antimüllerian hormone in healthy premenopausal women.What is the value of anti-Müllerian hormone in predicting the response to ovarian stimulation with GnRH agonist and antagonist protocols?Does AMH Reflect Follicle Number Similarly in Women with and without PCOS?Correlation of serum Anti-Müllerian hormone concentrations on day 3 of the in vitro fertilization stimulation cycle with assisted reproduction outcome in polycystic ovary syndrome patients.The value of anti-Mullerian hormone measurement in the long GnRH agonist protocol: association with ovarian response and gonadotrophin-dose adjustments.Anti-Mullerian hormone as a predictor of ovarian reserve in ART protocols: the hidden role of thyroid autoimmunityAnti-mullerian hormone cut-off values for predicting poor ovarian response to exogenous ovarian stimulation in in-vitro fertilizationAnti-Müllerian hormone (AMH) in female reproduction: is measurement of circulating AMH a useful tool?Serum anti-Müllerian hormone and inhibin B levels at ovulation triggering day can predict the number of immature oocytes retrieved in in vitro fertilization cycles.What is the optimal threshold of serum Anti-Müllerian hormone (AMH) necessary for IVM treatments?Increased gonadotrophin stimulation does not improve IVF outcomes in patients with predicted poor ovarian reserve.Elevated serum anti-Müllerian hormone in adolescents with polycystic ovary syndrome: relationship to ultrasound featuresFollicular-fluid anti-Mullerian hormone (FF AMH) is a plausible biochemical indicator of functional viability of oocyte in conventional in vitro fertilization (IVF) cycles.Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer.Serum anti-Müllerian hormone predicts ovarian response and cycle outcome in IVF patients.Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART).The effect of ovarian puncture on the endocrine profile of PCOS patients who undergo IVMAnti-mullerian and androgens hormones in women with polycystic ovary syndrome undergoing IVF/ICSI.Fertility preservation in girls and young women.Anti-Mullerian hormone dynamics during controlled ovarian hyperstimulation and optimal timing of measurement for outcome prediction.Is foetal hyperexposure to androgens a cause of PCOS?Interactions between androgens, FSH, anti-Müllerian hormone and estradiol during folliculogenesis in the human normal and polycystic ovary.Comparison of ovarian function markers in users of hormonal contraceptives during the hormone-free interval and subsequent natural early follicular phases.
P2860
Q21135308-DB1113E7-4BD4-417B-A73F-982A91A97F21Q26774060-E6242A00-2914-41FB-9118-7CE96CBCC005Q26851230-BA069AF4-0DE8-4768-BBAD-02232DDBE36CQ28278102-9C959955-94F5-408B-B76C-CC1362B64F3AQ30439646-D4D93325-DBD7-48E1-AE17-BACF15893592Q33636964-93031F16-BA3D-432B-B21D-FF51CD3429DFQ33888297-67F962B5-7F49-47B0-8E7F-C5C6B535A994Q33937262-63204900-E2E9-4C16-AB78-DEC593ECCC49Q34226336-BC022072-42F2-4937-ABC6-1DC8B9698614Q34415976-4F869655-3907-4987-A006-2F18E986BC5AQ34472471-CB9266B0-EE2C-43BC-A82D-2EB5ABFA5BFDQ34568747-E2C136F3-9FD4-4880-BAC2-D319D0D17DDBQ34700094-DCAF695E-E1C9-4582-BED9-484C2A164E1AQ34902729-21CACE0B-118E-487C-886B-B8F2143104C1Q35086102-A2052A92-7608-47F6-A33A-F549E6E70598Q35100279-64CE7173-2B1A-4D6A-833C-FCD5C394DE05Q35171104-3F6B5DE1-E916-421C-A4E5-A9483EE99D83Q35185385-2B5E2722-4568-42FB-897F-1F847C799C04Q35750252-3B0C73C7-6942-4D98-B272-B1EE6F9FD75DQ35901133-425145E0-9DB6-44F3-823C-BA834C92F9DAQ35946575-6415D516-22E9-45FF-8F05-14CEFDAE57BEQ35976287-861B14B9-8387-4EBE-84A3-55F84824B633Q36082015-2A0D185E-6A84-4D87-8731-E523C0F8CFA6Q36385559-6422D7F4-766B-4427-A03A-2B8869FE874AQ36483196-8979B1E3-2CAC-45EE-A982-DADA5DC27E9DQ36853993-C22B172F-3A47-4B96-B603-73F13721F020Q36966433-06C86B54-5842-4128-954F-A1E99D70DBF9Q36995774-6A2EE758-C32D-4A21-84C4-16C15B538B59Q37149533-FC2BBAB9-3F74-41DA-AC6D-B56B2CF2CA21Q37186656-D31A8F01-139A-4B8A-9AB3-6B134DDE6CB6Q37253591-7F2411B2-CF07-4AD4-98AC-BE1CF201F7D1Q37380100-2146DDFE-3896-4615-9CC5-28E1BA9079B1Q37606149-FF3261BF-3B92-4C1E-9A5B-1A85DCA5575DQ37607260-1643BBA2-E79F-4989-8C15-81D340B024EBQ37615506-605A4E82-C3DC-4674-84E0-8CFBDF2A42C2Q37875896-27384D0F-A7B6-4D5C-9875-FE642E4D9CC8Q38482450-8D843307-08F3-483E-B210-25D2BF72940FQ38771084-23BE8749-08D0-4EAC-A0F8-B3AB4C0AEF97Q38938581-4CB89B3A-350F-480D-9257-08ADD90CC568Q39888178-1FED7772-4E5D-42BA-9A8E-6D64D3D8B724
P2860
Anti-Müllerian hormone plasma levels in spontaneous menstrual cycle and during treatment with FSH to induce ovulation.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Anti-Müllerian hormone plasma ...... with FSH to induce ovulation.
@en
Anti-Müllerian hormone plasma ...... with FSH to induce ovulation.
@nl
type
label
Anti-Müllerian hormone plasma ...... with FSH to induce ovulation.
@en
Anti-Müllerian hormone plasma ...... with FSH to induce ovulation.
@nl
prefLabel
Anti-Müllerian hormone plasma ...... with FSH to induce ovulation.
@en
Anti-Müllerian hormone plasma ...... with FSH to induce ovulation.
@nl
P2093
P2860
P356
P1433
P1476
Anti-Müllerian hormone plasma ...... with FSH to induce ovulation.
@en
P2093
Annibale Volpe
Leo Fischer Tamaro
Paola Levratti
Raoul Orvieto
Simone Giulini
Stefania Malmusi
P2860
P304
P356
10.1093/HUMREP/DEH508
P407
P577
2004-09-30T00:00:00Z